MedDataX Logo

Caffein Consumption and Response Inhibition

NCT ID: NCT01815203

Last Updated: 2013-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2013-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

With the abundance of energy-dense foods that are designed for ease of consumption in the current environment, it is of importance to better understand the factors that may undermine the control of energy intake at healthy levels.

One of the factors that is potentially important in response inhibition is caffeine.

The aim is to assess the direct effects of caffeine on response inhibition, using a No Go/Go-task. We will also assess whether the presentation of food cues, i.e. as words or as pictures, modulate response inhibition different in restrained vs. non-restrained eaters.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In a blinded, randomized cross-over design, participants will receive either a capsule with caffeine or placebo at two separate occasions whereupon study tasks will be performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Eating Behavior Obesity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Caffeine effects Inhibitory control

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Caffeine

Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.

Group Type EXPERIMENTAL

Caffeine

Intervention Type DRUG

Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.

Placebo

Administration of placebo (one gelatin capsule containing starch) with subsequent cognitive tasks and food test.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administration of placebo with subsequent cognitive tasks and food test.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Caffeine

Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.

Intervention Type DRUG

Placebo

Administration of placebo with subsequent cognitive tasks and food test.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Only males
* 18 ≤ 35 years
* Healthy (self rated)
* Used to drink caffeine
* Used to eat breakfast regularly (≥ 5 times a week).
* Non-smokers

Exclusion Criteria

* BMI outside the range of 18,5 ≤ 25
* hypersensitivity for the ingredients of the foods under study
* being a vegan or vegetarian. Participants reported not using products that are artificially sweetened, nor sugar in coffee and/or tea
* Presence of any chronically disease and/or treatment with medication
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Uppsala University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pleunie Hogenkamp, PhD

Role: PRINCIPAL_INVESTIGATOR

Uppsala University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Uppsala University

Uppsala, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PH2013a

Identifier Type: -

Identifier Source: org_study_id